Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Results
-
Antiemetic Agent, Kytril®, Obtained Approval for Additional Indication
[PDF 183KB] -
Supplemental Biologics License Application Submitted to FDA for ACTEMRA®,
[PDF 181KB]
a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody,
Regarding Adult Rheumatoid Arthritis Indication -
Personnel Strategy toward Becoming
[PDF 502KB]
A “Top Japanese Pharmaceutical Company” -
Chugai to Establish
[PDF 181KB]
“Chugai Pharmabody Research Pte. Ltd.” in Singapore,
a New Company for Generating New Antibody Drugs -
Bisphosphonate Antiresorptive Agent,
[PDF 21KB]
Ibandronate Sodium Hydrate Injection,
Demonstrates Efficacy in Osteoporosis in Phase II/III Trial -
Announcing Change of Parent Company and Largest Shareholder (Principal Shareholder)
[PDF 104KB] -
Personnel Changes
[PDF 37KB] -
Introduction of iPad2 to Activities for Providing Information to Medical Professionals
[PDF 182KB] -
Anti-Cancer Agent, Herceptin®
[PDF 176KB]
Obtained Approval for Additional Indication and Dosage and Administration -
Supply Plan of "Tamiflu®" Anti-influenza Drug
[PDF 43KB] -
Contribution of Para-transit Vehicles to Welfare Services
[PDF 108KB] -
F. Hoffmann-La Roche Announces Third Quarter Sales 2011
[PDF 16KB] -
Chugai Presents an Anti-Cancer Charity "Medicine and Humor 2011"
[PDF 199KB] -
Results of the Pharmaceutical Affairs Subcommittee Regarding the Application of Epogin®
[PDF 96KB]
for Chemotherapy-Induced Anemia -
Anti-Cancer Agent, Avastin®
[PDF 175KB]
Obtained Approval for Additional Indication and Dosage and Administration of
“Inoperable or Recurrent Breast Cancer“ -
Peginterferon alfa-2a “Pegasys®”
[PDF 187KB]
Approved for Additional Indication of “Chronic Active Hepatitis B” -
Immunosuppressive Agent, CellCept® Obtains Approval for Additional Pediatric
[PDF 201KB]
Dosage and Administration for Prophylaxis of Organ Rejection in Renal Transplants -
Chugai Establishes Endowed Course at Waseda University
[PDF 68KB]
– Focus on Japan’s Leading Cause of Death: Cancer – -
Chugai Initiates Clinical Trials for Multiple In-Licensed Compounds
[PDF 212KB]
Utilizing the Personalized Healthcare Strategy -
Detection of Radioactive Material from RDF Incineration Ashes
[PDF 189KB]
at Chugai’s Fuji-Gotemba Research Laboratories -
Chugai to In-license BRAF Inhibitor Vemurafenib
[PDF 176KB] -
Antiemetic Agent, Kytril®
[PDF 171KB]
Filed for Additional Indication By
"Application Based on Evidence in the Public Domain" -
Organizational and Personnel Changes
[PDF 224KB] -
Roche's RoACTEMRA Approved in Europe for
[PDF 160KB]
Children Living with a Rare and Severe Form of Arthritis -
Differences between Consolidated Financial Outlook and Actual Results of Half Year ended June 30, 2011, and Revision of Consolidated Financial Outlook for Fiscal Year 2011 ending December 31, 2011
[PDF 72KB] -
F. Hoffmann-La Roche Announces 2011 Half Year Results
[PDF 21KB] -
Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra®"
[PDF 42KB]
Subcutaneous Injection Demonstrates Efficacy
in Rheumatoid Arthritis in Phase III Clinical Study -
Chugai Launches a Long-Acting Erythropoiesis Stimulating Agent, “Mircera® Injection Syringe”
[PDF 371KB] -
New Drug Application Filed for
[PDF 239KB]
Recombinant Human Deoxyribonuclease I (rhDNase) "Pulmozyme" -
Update on the Impact of the Great East Japan Earthquake
[PDF 22KB] -
Roche Returns Development and Marketing Rights of SGLT2 Inhibitor “CSG452”to Chugai
[PDF 16KB] -
Anti-Cancer Agent, Tarceva® Obtained Approval for Additional Indication of
[PDF 237KB]
“Pancreatic Cancer Not Amenable to Curative Resection“
and Measures for Proper Use -
Chronic Hepatitis C Treatment, Pegasys®, and Antiviral Drug, Copegus®, Obtained Approval for Additional Indication of
[PDF 282KB]
Compensated Liver Cirrhosis Related to Hepatitis C -
Determination of Terms and Conditions of Stock Options (Stock Acquisition Rights)
[PDF 50KB] -
Update on the Application of Epogin® in Chemotherapy-Induced Anemia
[PDF 103KB] -
Issuance of Stock Options (Stock Acquisition Rights)
[PDF 79KB] -
RoActemra Could Change the Current Standard of Treatment for
[PDF 193KB]
People Living with Rheumatoid Arthritis -
RoActemra Offers a New Option for
[PDF 65KB]
Children Living with a Rare and Severe Form of Arthritis -
Immunosuppressive Agent, CellCept® Filed for Pediatric Dosage and
[PDF 179KB]
Administration for Prevention of Organ Rejection in Renal Transplant
by “Application Based on Evidence in the Public Domain” -
Anti-Cancer Agent, Herceptin®
[PDF 168KB]
Filed for Additional Indication, and Dosage and Administration
By "New Drug Application Based on Evidence in the Public Domain" -
Long-Acting Erythropoiesis Stimulating Agent,
[PDF 186KB]
“Mircera® Injection Syringe,” Approved in Japan -
Revision of Financial Outlook for Fiscal Year 2011
[PDF 21KB]
(January 1 – December 31, 2011) -
Chronic Hepatitis C Treatment, Pegasys®, Designated for Priority Review
[PDF 173KB]
by Ministry of Health, Labour and Welfare for the Indication of Chronic Hepatitis B -
FDA Approves ACTEMRA for the Treatment of
[PDF 159KB]
Systemic Juvenile Idiopathic Arthritis (SJIA) -
F. Hoffmann-La Roche Announces First Quarter Sales 2011
[PDF 63KB] -
Launch of the Osteoporosis Agent “Edirol® Capsule”
[PDF 204KB] -
Impact of the Great East Japan Earthquake (No.3)
[PDF 17KB] -
Donation of "Tamiflu®" Anti-influenza Drug for the Support of
[PDF 188KB]
the Sufferers of the 2011 Off the Pacific Coast of Tohoku Earthquake -
Impact of the 2011 off the Pacific coast of Tohoku Earthquake (No.2)
[PDF 36KB] -
Impact of the 2011 off the Pacific coast of Tohoku Earthquake
[PDF 37KB] -
Relief Efforts Support for the Disaster Area
[PDF 167KB]
Struck by the 2011 Off the Pacific Coast of Tohoku Earthquake -
Anti-Cancer Agent, Herceptin®
[PDF 175KB]
Obtained Approval for Additional Indication of Advanced or Recurrent
Gastric Cancer Overexpressing HER2, Not Amenable to Curative Resection -
Anti-Cancer Agent, Xeloda® Obtained Approval for Additional Indication of Advanced or Recurrent Gastric Cancer, which is Not Amenable to Curative Resection
[PDF 172KB] -
Notice Regarding Dividend
[PDF 60KB] -
Information about Appointment of a New Accounting Auditor
[PDF 75KB] -
Personnel Changes
[PDF 51KB] -
Organizational and Personnel Changes
[PDF 214KB] -
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2010
[PDF 67KB] -
Pegasys ®, and Copegus ®, Designated for Priority Review by MHLW
[PDF 181KB]
for the Indication of Compensated Liver Cirrhosis Related to Hepatitis C -
Chronic Hepatitis C Treatment, Pegasys®,
[PDF 173KB]
Filed for Additional Indication of Chronic Hepatitis B -
Chugai Launches A New Disease Awareness Website for Rheumatoid Arthritis
[PDF 278KB] -
An Active Vitamin D3 Derivative “Edirol®,” Approved in Japan
[PDF 27KB] -
FDA Grants Supplemental Approval for ACTEMRA
[PDF 107KB]